BACKGROUND: The state of tolerance allows long term graft survival without immunosuppressants. Lung transplantation tolerance has not been consistently achieved in either small or large animal models. METHODS: The mechanisms and effectiveness of a tolerance induction protocol consisting of donor specific transfusion (DST; day 0) and a short course of co-stimulatory blockade (anti-CD154 antibody; days -7, -4, 0 and +4) were studied in the mouse heterotopic tracheal transplant model of chronic lung rejection. C57BL/6 mice received BALB/c tracheal grafts (day 0) and were treated with DST alone, anti-CD154 alone, the combination (DST/anti-CD154), or no treatment. No non-specific immunosuppressants were used. RESULTS: DST/anti-CD154 in combination, but neither treatment alone, markedly prolonged the lumen patency and survival (>100 days) of fully histo-incompatible allografts (p<0.05 versus control allografts at every time point studied up to 16 weeks) without immunosuppression. This protocol was donor antigen specific as third party grafts (C3H) were promptly rejected. In addition, DST/anti-CD154 did not result in mixed chimerism but induced transplantation tolerance via a peripheral mechanism(s), which included significantly reduced cytotoxic T cell activity (p<0.001) and a significantly increased percentage of CD4+CD25+ cells (p = 0.03). CONCLUSIONS: The DST/anti-CD154 protocol successfully induced and maintained long term, donor specific tolerance in the mouse heterotopic airway graft model of chronic lung rejection. This finding may lead us closer to successful tolerance induction in lung transplantation.
BACKGROUND: The state of tolerance allows long term graft survival without immunosuppressants. Lung transplantation tolerance has not been consistently achieved in either small or large animal models. METHODS: The mechanisms and effectiveness of a tolerance induction protocol consisting of donor specific transfusion (DST; day 0) and a short course of co-stimulatory blockade (anti-CD154 antibody; days -7, -4, 0 and +4) were studied in the mouse heterotopic tracheal transplant model of chronic lung rejection. C57BL/6 mice received BALB/c tracheal grafts (day 0) and were treated with DST alone, anti-CD154 alone, the combination (DST/anti-CD154), or no treatment. No non-specific immunosuppressants were used. RESULTS:DST/anti-CD154 in combination, but neither treatment alone, markedly prolonged the lumen patency and survival (>100 days) of fully histo-incompatible allografts (p<0.05 versus control allografts at every time point studied up to 16 weeks) without immunosuppression. This protocol was donor antigen specific as third party grafts (C3H) were promptly rejected. In addition, DST/anti-CD154 did not result in mixed chimerism but induced transplantation tolerance via a peripheral mechanism(s), which included significantly reduced cytotoxic T cell activity (p<0.001) and a significantly increased percentage of CD4+CD25+ cells (p = 0.03). CONCLUSIONS: The DST/anti-CD154 protocol successfully induced and maintained long term, donor specific tolerance in the mouse heterotopic airway graft model of chronic lung rejection. This finding may lead us closer to successful tolerance induction in lung transplantation.
Authors: K Onodera; A Chandraker; H D Volk; T Ritter; M Lehmann; H Kato; M H Sayegh; J W Kupiec-Weglinski Journal: Transplantation Date: 1999-07-27 Impact factor: 4.939
Authors: A Yamada; K Konishi; G L Cruz; M Takehara; M Morikawa; I Nakagawa; M Murakami; T Abe; S Todo; T Uede Journal: Transplantation Date: 2000-03-15 Impact factor: 4.939
Authors: Daniel Kreisel; Alexander S Krupnick; Andrew E Gelman; Friederike H Engels; Sicco H Popma; Alyssa M Krasinskas; Keki R Balsara; Wilson Y Szeto; Laurence A Turka; Bruce R Rosengard Journal: Nat Med Date: 2002-03 Impact factor: 53.440
Authors: David C Gondek; Victor Devries; Elizabeth C Nowak; Li-Fan Lu; Kathryn A Bennett; Zachary A Scott; Randolph J Noelle Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Cavit D Kant; Yoshinobu Akiyama; Katsunori Tanaka; Susan Shea; Sarah E Connolly; Sharon Germana; Henry J Winn; Christian LeGuern; Georges Tocco; Gilles Benichou Journal: J Immunol Date: 2013-07-05 Impact factor: 5.422
Authors: Ya D Karpova; V D Ustichenko; N M Alabedal'karim; A A Stepanova; Yu V Lyupina; K I Boguslavski; G A Bozhok; N P Sharova Journal: Acta Naturae Date: 2017 Jul-Sep Impact factor: 1.845